Xeltis starts European rollout of aXess after first commercial implant

The launch follows positive 12-month EU pivotal data and comes as the company’s U.S. pivotal trial has passed 50% enrollment.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.